A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome

European Journal of Immunology

Volumn 45, Issue 8, 2015, Pages 2183-2190

  Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Broadly neutralizing antibody; Fc receptor; Human immunodeficiency virus; Passive immunotherapy

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN CONSTANT REGION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT ACTIVATION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; VIRAL CLEARANCE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMAL; DISEASE MODEL; GENETICS; HAPLORHINI; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOLOGY; MOUSE; PASSIVE IMMUNIZATION; PROCEDURES; THERAPEUTIC USE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; HAPLORHINI; HIV ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN G; MICE; PROTEIN ENGINEERING;

EID: 84938827079     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445386     Document Type: Article

References (77)

1. Global AIDS response progress reportin 2013. In UNAIDS, W. U. (ed.), 188, UNAIDS, Geneva, 2013.
2. Albert, J., Berglund, T., Gisslen, M., Groon, P., Sonnerborg, A., Tegnell, A., Alexandersson, A. et al., Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand. J. Infect. Dis. 2014. 46: 673-677.
3. Frentz, D., van de Vijver, D., Abecasis, A., Albert, J., Hamouda, O., Jorgensen, L., Kucherer, C. et al., Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One 2014. 9: e94495.
4. Nelson, R., New CDC guidelines recommend circumcision to cut HIV risk. Lancet Infect. Dis. 2015. 15: 269-270.
5. Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L. and Nussenzweig, M. C., Antibodies in HIV-1 vaccine development and therapy. Science 2013. 341: 1199-1204.
6. Munier, C. M., Andersen, C. R. and Kelleher, A. D., HIV vaccines: progress to date. Drugs 2011. 71: 387-414.
7. Chung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A. S. et al., Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 2014. 6: 228ra238.
8. Dugast, A. S., Stamatatos, L., Tonelli, A., Suscovich, T. J., Licht, A. F., Mikell, I., Ackerman, M. E. et al., Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur. J. Immunol. 2014. 44: 2925-2937.
9. Karasavvas, N., Billings, E., Rao, M., Williams, C., Zolla-Pazner, S., Bailer, R. T., Koup, R. A. et al., The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012. 28: 1444-1457.
10. Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R. et al., Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012. 206: 431-441.
11. Yates, N. L., Liao, H. X., Fong, Y., deCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M. et al., Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 2014. 6: 228ra239.
12. Shingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J., Nason, M. C. et al., Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 2014. 211: 2061-2074.
13. Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E. et al., Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013. 503: 224-228.
14. Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A., Greene, K., Gao, H. et al., Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 2015. 89: 2659-2671.
15. Horwitz, J. A., Halper-Stromberg, A., Mouquet, H., Gitlin, A. D., Tretiakova, A., Eisenreich, T. R., Malbec, M. et al., HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA 2013. 110: 16538-16543.
16. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A. et al., Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013. 503: 277-280.
17. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H. et al., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000. 6: 207-210.
18. Abboud, N., Chow, S. K., Saylor, C., Janda, A., Ravetch, J. V., Scharff, M. D. and Casadevall, A., A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 2010. 207: 2395-2405.
19. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C. and Ravetch, J. V., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014. 158: 1243-1253.
20. Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G. et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011. 333: 850-856.
21. DiLillo, D. J., Tan, G. S., Palese, P. and Ravetch, J., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 2014. 20: 143-151.
22. Forthal, D. N. and Moog, C., Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 2009. 4: 388-393.
23. Halper-Stromberg, A., Lu, C. L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R. et al., Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014. 158: 989-999.
24. Hogarth, P. M. and Pietersz, G. A., Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 2012. 11: 311-331.
25. Nimmerjahn, F. and Ravetch, J. V., Fc gamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008. 8: 34-47.
26. Takai, T., Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002. 2: 580-592.
27. Lux, A., Yu, X., Scanlan, C. N. and Nimmerjahn F., Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J. Immunol. 2013. 190: 4315-4323.
28. Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S. and Daeron, M., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009. 113: 3716-3725.
29. Lux, A. and Nimmerjahn, F., Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 2013. 33(Suppl 1): S4-S8.
30. Nimmerjahn, F. and Ravetch, J. V., Fcgamma receptors: old friends and new family members. Immunity 2006. 24: 19-28.
31. Clynes, R. and Ravetch, J. V., Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995. 3: 21-26.
32. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. and Ravetch, J. V., Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 1998. 95: 652-656.
33. Takai, T., Li, M., Sylvestre, D., Clynes, R. and Ravetch, J. V., FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994. 76: 519-529.
34. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. and Tedder, T. F., Antibody isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 2006. 203: 743-753.
35. Beers, S. A., French, R. R., Chan, H. T., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S. et al., Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010. 115: 5191-5201.
36. Pallasch, C. P., Leskov, I., Braun, C. J., Vorholt, D., Drake, A., Soto-Feliciano, Y. M., Bent, E. H. et al., Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 2014. 156: 590-602.
37. Racila, E., Link, B. K., Weng, W. K., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J. et al., A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008. 14: 6697-6703.
38. Wang, S. Y., Racila, E., Taylor, R. P. and Weiner, G. J., NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008. 111: 1456-1463.
39. Wang, S. Y., Veeramani, S., Racila, E., Cagley, J., Fritzinger, D. C., Vogel, C. W., St John, W. et al., Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009. 114: 5322-5330.
40. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754-758.
41. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D. et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008. 26: 1789-1796.
42. Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J. and Levy, R., Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 2004. 22: 4717-4724. [Epub 2004 Oct 4713.]
43. Weng, W. K. and Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003. 21: 3940-3947. [Epub 2003 Sep 3915.]
44. Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G. et al., Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 2013. 12: 2031-2042.
45. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T. et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 2014. 370: 1101-1110.
46. Biburger, M., Lux, A. and Nimmerjahn, F., How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv. Immunol. 2014. 124: 67-94.
47. Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M. et al., Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011. 35: 932-944.
48. Gul, N., Babes, L., Siegmund, K., Korthouwer, R., Bogels, M., Braster, R., Vidarsson, G. et al., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 2014. 124: 812-823.
49. Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N. and Bousso, P., The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 2013. 123: 5098-5103.
50. Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M. and Tedder, T. F., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 2004. 199: 1659-1669.
51. Biburger, M. and Nimmerjahn, F., Low level of FcgammaRIII expression on murine natural killer cells. Immunol. Lett. 2012. 143: 53-59.
52. Lux, A., Seeling, M., Baerenwaldt, A., Lehmann, B., Schwab, I., Repp, R., Meidenbauer, N. et al., A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 2014. 7: 236-248.
53. DiLillo, D. J. and Ravetch, J. V., Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015. 161: 1035-1045.
54. Clynes, R. A., Towers, T. L., Presta, L. G. and Ravetch, J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000. 6: 443-446.
55. Nimmerjahn, F. and Ravetch, J. V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005. 310: 1510-1512.
56. Takai, T., Ono, M., Hikida, M., Ohmori, H. and Ravetch, J. V., Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996. 379: 346-349.
57. Corti, D. and Lanzavecchia, A., Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013. 31: 705-742.
58. Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C. et al., Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 2011. 108: 11181-11186.
59. Doria-Rose, N. A., Klein, R. M., Daniels, M. G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T. et al., Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010. 84: 1631-1636.
60. Walker, L. M., Phogat, S. K., Chan-Hui, P. Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T. et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009. 326: 285-289.
61. Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L. et al., The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011. 85: 4828-4840.
62. Mouquet, H. and Nussenzweig, M. C., HIV: roadmaps to a vaccine. Nature 2013. 496: 441-442.
63. Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. et al., Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007. 449: 101-104.
64. Klein, F., Halper-Stromberg, A., Horwitz, J. A., Gruell, H., Scheid, J. F., Bournazos, S., Mouquet, H. et al., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012. 492: 118-122.
65. Klein, F., Nogueira, L., Nishimura, Y., Phad, G., West, A. P., Jr., Halper-Stromberg, A., Horwitz, J. A. et al., Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 2014. 211: 2361-2372.
66. Caskey, M., Klein, F., Lorenzi, J. C., Seaman, M. S., West, A. P., Jr., Buckley, N., Kremer, G. et al., Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015. 522: 487-491.
67. Forthal, D. N., Gach, J. S., Landucci, G., Jez, J., Strasser, R., Kunert, R. and Steinkellner, H., Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 2010. 185: 6876-6882.
68. Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. and Metzger, D. W., Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001. 166: 7381-7388.
69. Bournazos, S., Chow, S. K., Abboud, N., Casadevall, A. and Ravetch, J. V., Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 2014. 124: 725-729.
70. Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002. 277: 26733-26740. [Epub 22002 May 26731.]
71. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K. et al., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003. 278: 3466-3473. [Epub 2002 Nov 3468.]
72. Ferrara, C., Grau, S., Jager, C., Sondermann, P., Brunker, P., Waldhauer, I., Hennig, M. et al., Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 2011. 108: 12669-12674.
73. Moldt, B., Shibata-Koyama, M., Rakasz, E. G., Schultz, N., Kanda, Y., Dunlop, D. C., Finstad, S. L. et al., A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 2012. 86: 6189-6196.
74. Gomez-Roman, V. R., Patterson, L. J., Venzon, D., Liewehr, D., Aldrich, K., Florese, R. and Robert-Guroff, M., Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 2005. 174: 2185-2189.
75. Florese, R. H., Van Rompay, K. K., Aldrich, K., Forthal, D. N., Landucci, G., Mahalanabis, M., Haigwood, N. et al., Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 2006. 177: 4028-4036.
76. Roopenian, D. C. and Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007. 7: 715-725.
77. Ko, S. Y., Pegu, A., Rudicell, R. S., Yang, Z. Y., Joyce, M. G., Chen, X., Wang, K. et al., Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014. 514: 642-645.